Ally Bridge Group (Ny) LLC Verve Therapeutics, Inc. Transaction History

Ally Bridge Group (Ny) LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$11.14 - $23.17 $1.17 Million - $2.44 Million	-105,360 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$20.92 - $39.36 $104,600 - $196,800	-5,000 Reduced 4.53%	105,360 $2.4 Million
Q4 2021 Feb 14, 2022	BUY	$31.94 - $54.82 $3.05 Million - $5.23 Million	95,360 Added 635.73%	110,360 $4.07 Million
Q3 2021 Nov 15, 2021	BUY	$46.0 - $73.99 $690,000 - $1.11 Million	15,000 New	15,000 $705,000

186

73.3M

85K

215K

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $346M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

Get notified when there are updates to the investment portfolio of Ally Bridge Group (Ny) LLC, based on Form 13F filings with the SEC.

Stay updated on Ally Bridge Group (Ny) LLC with notifications on news.